Core Insights - Hualing Pharmaceutical-B (02552) saw a significant stock increase, closing up over 4% and reaching a trading volume of 16.7041 million HKD [1] - The company’s core product, Dapagliflozin, is the first glucose kinase activator (GKA) approved globally in 2022, with rapid sales growth expected after regaining commercialization rights in 2025 [1] - The company reported a 110% year-on-year revenue increase in the first half of the year, driven by deferred income from Bayer, leading to profitability [1] - Hualing Pharmaceutical-B is developing a second-generation GKA using sustained-release technology and has submitted a clinical application to the FDA, indicating a focus on international expansion [1] - The GKA market is evolving with the first drug commercialized and second-generation products advancing, positioning Hualing Pharmaceutical-B as a key player in this sector with no other listed companies currently advancing similar core pipelines [1] Research and Development - A real-world study involving 2,000 type 2 diabetes patients across 80 centers in China confirmed the broad applicability and safety of Dapagliflozin [2] - New research findings on diabetes remission and cognitive improvement further solidify Hualing Pharmaceutical-B's global leadership in GKA research and treatment [2]
港股异动 | 华领医药-B(02552)尾盘涨超4% 公司第二代GKA已向FDA提交临床申请 行业研发处于领先地位